The Hyderabad-based drug major remains confident about sustaining its growth momentum and driving value creation across all businesses. (Image: Glsun Mall on Unsplash) Show Quick Read Summary is AI Generated. Newsroom Reviewed

Aurobindo Pharma is currently incurring a loss at its China-based facility and expects the plant to achieve break-even by the end of the fiscal year, according to its CFO S Subramanian.

The Hyderabad-based drug major remains confident about sustaining its growth momentum and driving value creation across all businesses, he said.

"China (plant), as on date in the quarter, I will be incurring a loss of around maybe a million dollars, but, probably, we will be able to achieve the break-even between Q3 and Q4 and after that, China will start moving up in the over

See Full Page